<DOC>
	<DOCNO>NCT00225992</DOCNO>
	<brief_summary>In phase II study besides evaluate safety , primary efficacy parameter evaluate incidence patient response Trisenox evidence increase blood count ( red , white , platelet ) and/or decrease transfusion dependency . The secondary efficacy parameter assessment tolerability new dose schedule . Arsenic trioxide administer intravenously 1 2 hour load dose 0.30mg/kg day 1-5 first week twice weekly 27 week total 28 week .</brief_summary>
	<brief_title>Phase II Research Study Arsenic Trioxide ( Trisenox ) Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Diagnosis Myelodysplastic Syndrome FAB . Can make cytogenetic analysis Bone Marrow Hematologist evaluation Patient must bone marrow biopsy aspiration confirm diagnosis within 60 day prior treatment ECOG performance status 02 An EKG must perform within 7 day prior treatment confirm QT interval &lt; 460msec . Serum creatinine less equal 2.5 time upper limit normal . Serum bilirubin less equal 2.5 time upper limit normal . Serum potassium great equal 4.0 mEq/dL serum magnesium great equal 1.8 mg/dL . If serum electrolyte specify limit baseline laboratory test , electrolyte administer bring serum concentration level administer arsenic trioxide . Patients must 18 year age participate study Pregnant nursing woman , men woman childbearing potential unwilling employ adequate contraception . Corrected QT interval great equal 460msec presence serum potassium magnesium value within normal range . Significant CHF , coronary ischemia serious Arrhythmias include conduction delay . Peripheral neuropathy great equal 2 . Evidence active infection Concurrent treatment maintenance therapy , cytotoxic chemotherapy , radiation , investigational agent . Inability unwillingness comply treatment protocol , follow , research test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>